TickerFacts.

Company research / HRMY

Harmony Biosciences Holdings, Inc. (HRMY)

Build a valuation ↗↓ Download CSV

CIK 0001802665 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Harmony Biosciences Holdings, Inc. reported revenue of $868.45M. Revenue grew 21.5% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $959.90M.

Key ratios (year ended 2025-12-31)

77.2%
Gross margin
24.0%
Operating margin
18.3%
Net margin
18.2%
Return on year-end equity
21.5%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-13

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$959.90M$868.45M$714.73M$582.02M$437.86M$305.44M$159.74M$6.00M
Cost of Revenue$235.91M$198.34M$156.81M$121.24M$83.48M$55.52M$27.74M$1.58M
Gross Profit$723.99M$670.11M$557.92M$460.79M$354.37M$249.92M$132.00M$4.42M
R&D Expense$220.87M$189.59M$145.82M$76.06M$70.89M$30.37M$19.45M$69.59M
Operating Income$230.65M$208.47M$190.83M$192.03M$120.19M$87.53M$16.99M-$145.90M
Net Income$181.27M$158.69M$145.49M$128.85M$181.47M$34.60M-$36.94M-$151.98M
EPS (Diluted)n/a$2.71$2.51$2.13$2.97$0.58-$2.48-$24.07
Total Assets$1.37B$1.27B$999.20M$811.45M$673.87M$433.44M$427.07M$106.70M
Total Liabilities$373.84M$401.41M$340.05M$344.46M$271.03M$246.94M$329.89M$118.29M
Long-Term Debt$153.96M$163.66M$179.27M$193.57M$191.65Mn/an/an/a
Shareholders' Equity$999.24M$870.22M$659.15M$466.99M$402.84M$186.51M$97.18M-$422.86M
Cash & Equivalents$549.77M$752.50M$453.00M$311.66M$243.78M$234.31M$228.63M$24.46M
Operating Cash Flow$355.08M$348.20M$219.82M$219.39M$144.47M$98.56M-$2.98M-$75.44M
Capital Expendituresn/a$310.0K$1.15M$312.0K$172.0K$298.0K$2.0K$149.0K
Free Cash Flown/a$347.89M$218.67M$219.07M$144.29M$98.26M-$2.99M-$75.58M
Share Repurchasesn/an/an/a$100.00Mn/an/a$167.0Kn/a
Shares Outstanding58.12M57.73M57.14M56.77M59.62M58.83M56.89M7.79M
Weighted Average Diluted Sharesn/a58.54M57.87M60.37M61.10M59.21M25.77M7.78M
EPS (Basic)n/a$2.76$2.56$2.17$3.07$0.60-$2.48-$24.07

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView